Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis

Pakistan Journal of Medical Sciences

Volumn 29, Issue 3, 2012, Pages

  Abdul Wahab, Asrul ^a   Mohammad, Marlyn ^a   Rahman, M M ^a   Mohamed Said, Mohd Shahrir ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Anti CCP; Negative predictive value; Positive predictive value; Rheumatoid arthritis; Rheumatoid factor; Sensitivity; Specificity

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

EID: 84876917556     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.293.2924     Document Type: Article

References (19)

1. Balsa A, Cabezon A, Orozco G, Cobo T, Miranda-Carus E, Lopez-Nevot ML, et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther. 2010;12(2):R62.
2. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmunity Review. 2011;9:216-223.
3. Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC. Smoking increases rheumatoid arthritis susceptibility in individuals carrying HLA-DRB1 Shared Epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis & Rheumatism. 2010;62(2):369-377.
4. Arthritis Foundation Malaysia website at http://www.afm. org.my. Last assessed on 23 July 2012.
5. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systemic literature review. Ann Rheum Dis. 2006;65(7):845-851.
6. Sauerland U, Becker H, Seidel M, Schotte H, Willeke P, Schorat A, et al. Clinical utility of anti-CCP assay: Experiences with 700 patients. Annals of the New York Academy of Science. 2005;1050:314-318.
7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-1588.
8. Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int. 2012;32(2):361-366.
9. Hui L, Wuqi S, Yang L, Yanhong L, Jing B, Xiu L, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity. Clin Rheumatol. 2010;29(4):413-417.
10. Sockalingam S, Khuan CS, Sthaneshwar P. Prevalence of anti-cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity. Int J Rheum Dis. 2009;12:211-215.
11. Gomez EL, Gun SC, Somnath SD, D'Souza B, Lim AL, Chinna K, et al. The prevalence of rheumatoid factor isotypes and anti-cyclic citrullinated peptides in Malaysian rheumatoid arthritis patients. Int J Rheum Dis. 2011;14(1):12-17.
12. Cader MZ, Filer AD, Buckley CD, Raza K. The relationship between presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. BMC Musculoskeletal Disorders. 2010;11:187-191.
13. Goeldner I, Skare TL, Reason ITM, Nisihara RM, Silva MB, Utiyama SRDR. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology. 2010;49:1590-1593.
14. Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. Q J Med. 2007;100:193-201.
15. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis. 2003;62:870-874.
16. Jaskowski TD, Hill HR, Rusco KL, Lakos G, Szekanecz Z, Teodorescu M. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol. 2010;37:1582-1588.
17. Ohmura K, Terao C, Maruya E, Katayama M, Matoba K, Shimada K, et al. Anti-citrullinated peptide antibody negative RA is a genetically distinct subset: A definitive study using only bone erosive ACPA-negative rheumatoid arthritis. Rheumatology. 2010;49(12):2298-2304.
18. Lindqvsit E, Eberhardt K, Bendtzen K. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64:196-201.
19. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808.